Aurinia Pharmaceuticals: Assessing Valuation After 80% Surge and Lupus Nephritis Momentum

Aurinia Pharmaceuticals has surged 80.7% YTD and 64.6% over the last year, driven by optimism around its lupus nephritis therapy and commercial execution. The stock scores a 3/6 valuation check score, indicating it is undervalued on half of the key metrics tracked. A discounted cash flow analysis suggests the stock is about 53.7% undervalued, implying market participants may not be fully accounting for Aurinia's potential future cash generation.